How Pharmaceutical Companies Decide Which Markets to Enter

Pharmaceutical companies operate with a focus on innovation aligning with patient needs, commercial opportunity, regulatory requirements, and internal capabilities. Before investing in a new therapeutic area, geographic region, or patient population, companies must evaluate whether the opportunity justifies the financial, operational, and strategic commitment required. Market entry decisions can involve launching an existing medicine in a new country, expanding into a different disease indication, introducing a new formulation, or developing an entirely new therapeutic product.¹ These decisions require cross-functional collaboration among commercial, medical, regulatory, market access, finance, and research and development teams.

One of the first considerations in market entry is the size of the potential market and its expected growth. Pharmaceutical companies estimate the number of patients affected by a disease, the proportion who are diagnosed, the percentage eligible for treatment, and the number likely to receive the proposed medicine. These estimates help determine the potential patient population and the revenue opportunity.² Analysts also evaluate disease prevalence and incidence, treatment rates, prescribing patterns, and projected changes in demand. For example, an aging population or an increase in disease diagnosis may expand demand for certain treatments over time. Companies must also consider treatment affordability, access to healthcare, availability of alternatives, and the likelihood that patients will start and remain on therapy.

Market attractiveness depends on many different factors, including disease prevalence, unmet medical needs, availability of approved therapies, and an ability to establish clinical efficacy.³ A medicine that meaningfully addresses an important unmet need may offer a compelling reason to enter a market even when the patient population is relatively small. This is particularly relevant in rare diseases where a targeted therapy may provide substantial value to a defined group of patients. At the same time, companies must understand which competitors already serve the target population and how their products are positioned. Competitive assessments examine current market share, products in clinical development, treatment guidelines, clinical trial results, safety profiles, dosing schedules, and routes of administration.⁴ Companies also consider whether competitors benefit from established relationships with healthcare professionals, strong brand recognition, broad insurance coverage, or substantial real-world evidence. The competitive landscape can change rapidly as new medicines receive approval or brands receive approval for additional indications. A market with several established therapies may still offer a beneficial opportunity if a new product provides a meaningful clinical advantage or addresses an underserved patient segment. Conversely, a scientifically promising medicine may struggle if competitors already deliver similar benefits at lower prices or have secured favorable formulary access.

Regulatory considerations involving the FDA influence both the feasibility and timing of US market entry. As a result, pharmaceutical companies must understand the evidence and documentation required by the relevant regulatory authority before a medicine can be marketed. Other countries and regions have their own regulatory agencies, approval procedures, labeling requirements, and post-marketing obligations. Companies entering a new geographic market must determine whether existing clinical data will support the required submission or whether additional studies, manufacturing documentation, or local data may be needed. They must also consider regulatory review timelines, inspection requirements, pharmacovigilance obligations, and restrictions on promotional activities. Differences in regulatory requirements can increase development costs and delay commercialization, making some markets more feasible than others.

A company's internal research and development pipeline is another major determinant of market entry strategy. Pharmaceutical companies evaluate opportunities while considering their existing scientific expertise, development programs, intellectual property, and long-term portfolio goals. If important capabilities are missing, companies may pursue partnerships, licensing agreements, acquisitions, or collaborations. Companies also assess supply chain considerations including production capacity, raw material availability, supplier reliability, quality systems, transportation infrastructure, and local distribution partnerships. As a result, operational feasibility must be evaluated alongside market demand rather than treated as an issue to address only after a market has been selected.

Market entry is a multifaceted decision that requires companies to balance patient needs, scientific evidence, commercial potential, regulatory feasibility, and internal capabilities. Market size and growth help establish opportunities, while unmet medical need and competitive differentiation indicate whether a new treatment can have clinical and commercial success. Pricing and reimbursement determine whether patients can access the medicine. Regulatory requirements, manufacturing capabilities, geographic differences, and pipeline capabilities further influence the timing, cost, and feasibility of entry. High potential markets involve a company being able to deliver meaningful clinical value, establish a viable path to patient access, and achieve sustainable returns while meeting its obligations to patients and healthcare systems. Understanding the decision-making process helps pharmacy, nursing, medical, business, and healthcare students appreciate how scientific innovation becomes an actual treatment in real-world practice.

References:

1. Mills M, Michaeli D, Miracolo A, Kanavos P. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Serv Res. 2023;23(1):150.
2. Lublóy Á. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.
3. Sendyona S, Odeyemi I, Maman K. Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. J Mark Access Health Policy. 2016;4:10.3402.
4. Sheng J, Zhang T. Advancing drug development with "Fit-for-Purpose" modeling informed approaches. J Pharmacokinet Pharmacodyn. 2025;52(5):52.

*Information presented on RxTeach does not represent the opinion of any specific company, organization, or team other than the authors themselves. No patient-provider relationship is created.